All News

DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Belimumab in Lupus Nephritis

Jack Cush, MD

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.

Read Article
brain,pain,perception,cns

Orbitofrontal Cortex Implants to Assess Chronic Pain

Jack Cush, MD

Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling. 

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
lupus_0.jpg

Lupus Landmark Study to Accelerate Personalized Lupus Treatments

EurekAlert!

The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.

Read Article
DXA1.jpg (keep)

FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women

EurekAlert!

The commonly used Fracture Risk Assessment Tool (FRAX), which includes self-identified race and ethnicity information, and the Osteoporosis Self-Assessment Tool (OST), which does not, had suboptimal performance in determining major osteoporotic fracture risk across racial/ethnic categories in you

Read Article
ANCA, vasculitis, test

International Consensus on ANCA-Associated Vasculitis with Glomerulonephritis

Jack Cush, MD

Nephrology Dialysis Transplantation has published an overview of the management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis based on several international guidelines, including those frorm the ACR 2021, EULAR 2022 and KDIGO 2021 (Kidney Disease: Improving

Read Article
RheumNow Podcast square

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Read Article
Rheumatoid,RA,nodules,damage

Peresolimab's Potential in Rheumatoid Arthritis

Jack Cush, MD

Peresolimab is a humanized IgG1 monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active rheumatoid arthritis (RA). 

Read Article
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2

Links:

Dr. John Cush RheumNow ( View Tweet)
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Ph 3 study 800 ICU pts w/ severe community acq pneumonia shows those on IV hydrocortisone had lower mortality at day 28 (6.2% vs 11.9%; P=0.006), less intubation (18% vs 29.5%), less vasopressors (15% v 25%) vs PBO; no Diff w/ infx rates or GI bleed https://t.co/BjIM8UJXZS https://t.co/389CZovrZm

Links:

Dr. John Cush RheumNow ( View Tweet)
Allergic Drug - Induced Arthritis Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies. https://t.co/AmpWG2Siii https://t.co/PwEgVHfDu8

Links:

Dr. John Cush RheumNow ( View Tweet)
MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/xGPSA2oRis https://t.co/y7M42DlM7d

Links:

Dr. John Cush RheumNow ( View Tweet)
TNF Inhibitors and Acne? A literature review found 47 refractory acne pts Rx w/ TNFi; noting partial improvement (94%) or clearance (40%) & only 6% w/ adverse events. 17 pts had new-onset acne after Rx w/ TNFi for a different inflamm Dx. Odd! https://t.co/duHEIHBMyK https://t.co/br8NQZQE2r

Links:

Dr. John Cush RheumNow ( View Tweet)
Avacopan in GPA - non-inferior to prednisone for induction remission - received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids - should be used in newly diagnosed active or relapsing disease @rheumnow #RNL2023 https://t.co/My6M5MGBl1 https://t.co/0aPFUeE55Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Carol Langford #RNL2023 Use of CYC + RTX: Not routine upfront, but may be needed for escalating disease Limited data to support initial usage Higher risk of hypogammaglobulinemia, infection, and death @RheumNow https://t.co/DRLf1Zl5bN https://t.co/fSv5ciAklI

Links:

Dr. John Cush RheumNow ( View Tweet)
Carol Langford #RNL2023 @RheumNow Rx options for GPA showed by targeted to patient's disease characteristics of severe vs non-severe disease CYC not for non-severe due to toxicity MTX, MMF not for severe disease https://t.co/jw3wq2k7gb https://t.co/y3ck6KuCDj

Links:

Dr. John Cush RheumNow ( View Tweet)
Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK "at-risk" population are patients Age ≥65 years or ever smoker who exhibited the excess adverse events (malignancies, MACE, MI, VTE, all-cause death) comparedd to TNFi (HRs 1.41–5.19) https://t.co/k78WsPR1Mv https://t.co/JmTDSctIa0

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Our old friend, hydroxychloroquine https://t.co/NouJayD0T3 https://t.co/lRBl0UQuY3

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×